How effective is efinaconazole in the management of onychomycosis?

References

• Faergemann J, Baran R. Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol. 2003;149(Suppl 65):1–4.
   PubMed Web of Science ®Google Scholar
• Foster KW, Ghannoum MA, Elewski BE. Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol. 2004;50:748–752.
   PubMed Web of Science ®Google Scholar
• Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000;43:641–648.
   PubMed Web of Science ®Google Scholar
• Kaur R, Kashyap B, Bhalla P. Onychomycosis–epidemiology, diagnosis and management. Indian J Med Microbiol. 2008;26:108–116.
   PubMed Web of Science ®Google Scholar
• Scher RK, Rich P, Pariser D, et al. The epidemiology, etiology, and pathophysiology of onychomycosis. Semin Cutan Med Surg. 2013;32:S2–4.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians’ offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol. 2000;43:244–248.
   PubMed Web of Science ®Google Scholar
• Elewski BE. Onychomycosis. Treatment, quality of life, and economic issues. Am J Clin Dermatol. 2000;1:19–26.
   PubMedGoogle Scholar
• Scher RK, Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol. 2003;149(Suppl 65):5–9.
   PubMed Web of Science ®Google Scholar
• Piraccini BM, Sisti A, Tosti A. Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. J Am Acad Dermatol. 2010;62:411–414.
   PubMed Web of Science ®Google Scholar
• Scher RK, Breneman D, Rich P, et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998;38:S77–86.
   Google Scholar
• Gupta AK, Paquet M, Simpson F, et al. Terbinafine in the treatment of dermatophyte toenail onychomycosis: a meta-analysis of efficacy for continuous and intermittent regimens. J Eur Acad Dermatol Venereol. 2013;27:267–272.
   PubMed Web of Science ®Google Scholar
• Lamisil. Package insert: LAMISIL (terbinafine hydrochloride) tablets, 250 mg Drugs@FDA: FDA approved drug products 2012 [Internet]. 2012. Available from: www. accessdata.fda.gov/drugsatfda_docs/label/ 2012/020539s021lbl.pdf
   Google Scholar
• Lavrijsen AP, Balmus KJ, Nugteren-Huying WM, et al. Hepatic injury associated with itraconazole. Lancet Lond Engl. 1992;340:251–252.
   PubMed Web of Science ®Google Scholar
• Sporanox. Package insert: SPORANOX! (itraconazole) Capsules. Drugs@FDA: FDA approved drug products 2012 [Internet]. 2012. Available from: www.accessdata.fda.gov/ drugsatfda_docs/label/2012/020083s048s049s050lbl.pdf
   Google Scholar
• Dermik Laboratories. Penlac nail lacquer (ciclopirox) topical solution, 8% [Internet]. 2004. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21022s004lbl.pdf
   Google Scholar
• Kerydin. Package insert: Kerydin (tavaborole) topical solution, 5% [Internet]. 2014. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2014/204427s000lbl. pdf
   Google Scholar
• Elewski BE, Aly R, Baldwin SL, et al. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies. J Am Acad Dermatol. 2015;73:62–69.
   PubMed Web of Science ®Google Scholar
• Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68:600–608.
   PubMed Web of Science ®Google Scholar
• Ogura H, Kobayashi H, Nagai K, et al. Synthesis and antifungal activities of (2R,3R)-2-aryl-1-azolyl-3-(substituted amino)-2-butanol derivatives as topical antifungal agents. Chem Pharm Bull (Tokyo). 1999;47:1417–1425.
   PubMed Web of Science ®Google Scholar
• United States Adopted Names Council. Statement on a nonproprietary name adopted by the USAN Council: efinaconazole. Available from: www.amaassn.org/resources/doc/usan/efinaconazole.pdf
   Google Scholar
• Sakamoto M, Sugimoto N, Kawabata H, et al. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails. J Drugs Dermatol. 2014;13:1388–1392.
   PubMed Web of Science ®Google Scholar
• Tschen EH, Bucko AD, Oizumi N, et al. Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind study. J Drugs Dermatol. 2013;12:186–192.
   PubMed Web of Science ®Google Scholar
• LLC VPNA. Jublia (Efinaconazole) Package Insert [Internet]. 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203567s000lbl.pdf
   Google Scholar
• Rodriguez RJ, Low C, Bottema CD, et al. Multiple functions for sterols in Saccharomyces cerevisiae. Biochim Biophys Acta. 1985;837:336–343.
   PubMed Web of Science ®Google Scholar
• Parks LW, Smith SJ, Crowley JH. Biochemical and physiological effects of sterol alterations in yeast–a review. Lipids. 1995;30:227–230.
   PubMed Web of Science ®Google Scholar
• Tatsumi Y, Nagashima M, Shibanushi T, et al. Mechanism of action of efinaconazole, a novel triazole antifungal agent. Antimicrob Agents Chemother. 2013;57:2405–2409.
   PubMed Web of Science ®Google Scholar
• Jo Siu WJ, Tatsumi Y, Senda H, et al. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob Agents Chemother. 2013;57:1610–1616.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Drummond-Main C, Cooper EA, et al. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment. J Am Acad Dermatol. 2012;66:494–502.
   PubMed Web of Science ®Google Scholar
• Summerbell RC. Epidemiology and ecology of onychomycosis. Dermatology. 1997;194(Suppl 1):32–36.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Miyamoto M, Sugibayashi K, et al. Drug permeation through the three layers of the human nail plate. J Pharm Pharmacol. 1999;51:271–278.
   PubMed Web of Science ®Google Scholar
• Arika T, Yokoo M, Hase T, et al. Effects of butenafine hydrochloride, a new benzylamine derivative, on experimental dermatophytosis in guinea pigs. Antimicrob Agents Chemother. 1990;34:2250–2253.
   PubMed Web of Science ®Google Scholar
• Sugiura K, Sugimoto N, Hosaka S, et al. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment. Antimicrob Agents Chemother. 2014;58:3837–3842.
   PubMed Web of Science ®Google Scholar
• Kircik LH. Enhancing transungual delivery and spreading of efinaconazole under the nail plate through a unique formulation approach. J Drugs Dermatol. 2014;13:1457–1461.
   PubMed Web of Science ®Google Scholar
• Elewski BE, Pollak RA, Pillai R, et al. Access of efinaconazole topical solution, 10%, to the infection site by spreading through the subungual space. J Drugs Dermatol. 2014;13:1394–1398.
   PubMed Web of Science ®Google Scholar
• Zeichner JA, Stein Gold L, Korotzer A. Penetration of ((14)C)-efinaconazole topical solution, 10%, does not appear to be influenced by nail polish. J Clin Aesthetic Dermatol. 2014;7:34–36.
   PubMedGoogle Scholar
• Gupta AK, Pillai R. The presence of an air gap between the nail plate and nail bed in onychomycosis patients: treatment implications for topical therapy. J Drugs Dermatol. 2015;14:859–863.
   PubMed Web of Science ®Google Scholar
• Aventis Pharmaceuticals Inc. PENLAC nail lacquer topical solution 8% package insert. Lansdale (PA): Aventis Pharm. Inc; 2004.
   Google Scholar
• Valeant Canada LP. PrJUBLIA^TM efinaconazole topical solution, 10% w/w. Ottawa (ON): Health Canada Drug Product Database; 2013.
   Google Scholar
• Jarratt M, Siu WJ, Yamakawa E, et al. Safety and pharmacokinetics of efinaconazole 10% solution in healthy volunteers and patients with severe onychomycosis. J Drugs Dermatol. 2013;12:1010–1016.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Mueller EA, Zehender H, et al. Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. Antimicrob Agents Chemother. 1995;39:2738–2741.
   PubMed Web of Science ®Google Scholar
• Hamilton JB, Terada H, Mestler GE. Studies of growth throughout the lifespan in Japanese: growth and size of nails and their relationship to age, sex, heredity, and other factors. J Gerontol. 1955;10:401–415.
   PubMedGoogle Scholar
• Zhi-Wei W, Jia-Ying X, Yang J, et al. Fingernail growth rate and macroelement levels determined by ICP-OES in healthy Chinese college students. Pol J Env Stud. 2012;21:1067–1070.
   Web of Science ®Google Scholar
• Gupta G, Dhruw V, Athawal B, et al. Human nail growth pattern and medicolegal aspect. J Indian Acad Forensic Med. 2005;27:87–91.
   Google Scholar
• Gupta AK, Elewski BE, Sugarman JL, et al. The efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: a pooled analysis of two phase 3 randomized trials. J Drugs Dermatol. 2014;13:815–820.
   PubMed Web of Science ®Google Scholar
• Walling HW, Sniezek PJ. Distribution of toenail dystrophy predicts histologic diagnosis of onychomycosis. J Am Acad Dermatol. 2007;56:945–948.
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Steingrimsson O. Risk factors associated with onychomycosis. J Eur Acad Dermatol Venereol. 2004;18:48–51.
   PubMed Web of Science ®Google Scholar
• Svejgaard EL, Nilsson J. Onychomycosis in Denmark: prevalence of fungal nail infection in general practice. Mycoses. 2004;47:131–135.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Konnikov N, MacDonald P, et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol. 1998;139:665–671.
   PubMed Web of Science ®Google Scholar
• Papini M, Cicoletti M, Fabrizi V, et al. Skin and nail mycoses in patients with diabetic foot. G Ital Dermatol E Venereol Organo Uff Soc Ital Dermatol E Sifilogr. 2013;148:603–608.
   PubMed Web of Science ®Google Scholar
• Pierard GE, Pierard-Franchimont C. The nail under fungal siege in patients with type II diabetes mellitus. Mycoses. 2005;48:339–342.
   PubMed Web of Science ®Google Scholar
• Vlahovic TC, Joseph WS. Efinaconazole topical, 10% for the treatment of toenail onychomycosis in patients with diabetes. J Drugs Dermatol. 2014;13:1186–1190.
   PubMed Web of Science ®Google Scholar
• Markinson BC, Caldwell BD. Efinaconazole topical solution, 10%: efficacy in patients with onychomycosis and coexisting tinea pedis. J Am Podiatr Med Assoc. 2015 Apr 13;105(5):407–411.
   PubMed Web of Science ®Google Scholar
• Rich P. Efinaconazole topical solution, 10%: the benefits of treating onychomycosis early. J Drugs Dermatol. 2015;14:58–62.
   PubMed Web of Science ®Google Scholar
• Rodriguez DA. Efinaconazole topical solution, 10%, for the treatment of mild and moderate toenail onychomycosis. J Clin Aesthetic Dermatol. 2015;8:24–29.
   PubMedGoogle Scholar
• Jellinek NJ, Korotzer A. Prognostic factors for complete cure following treatment of mild and moderate toenail onychomycosis with efinaconazole topical solution 10. J Drugs Dermatol. 2015;14:871–875.
   PubMed Web of Science ®Google Scholar
• Tosti A, Elewski BE. Treatment of onychomycosis with efinaconazole 10% topical solution and quality of life. J Clin Aesthetic Dermatol. 2014;7:25–30.
   PubMedGoogle Scholar
• Lipner SR, Scher RK. Management of onychomycosis and co-existing tinea pedis. J Drugs Dermatol. 2015;14:492–494.
   PubMed Web of Science ®Google Scholar
• Hirohata A, Hanafusa T, Mabuchi-Kiyohara E, et al. Contact dermatitis caused by efinaconazole solution for treatment of onychomycosis. Contact Dermatitis. 2015;73:190–192.
   PubMed Web of Science ®Google Scholar
• Jo W, Glynn M, Nejishima H, et al. Nonclinical safety assessment of Efinaconazole Solution (10%) for onychomycosis treatment. Regul Toxicol Pharmacol. 2014;70:242–253.
   PubMed Web of Science ®Google Scholar
• Glynn M, Jo W, Minowa K, et al. Efinaconazole: developmental and reproductive toxicity potential of a novel antifungal azole. Reprod Toxicol Elmsford N. 2015;52:18–25.
   PubMed Web of Science ®Google Scholar
• Del Rosso JQ, Reece B, Smith K, et al. Efinaconazole 10% solution: a new topical treatment for onychomycosis: contact sensitization and skin irritation potential. J Clin Aesthetic Dermatol. 2013;6:20–24.
   Google Scholar
• Canada. Health Canada, Summary of basis decision: Jublia Canada. 2014. Available from: www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2013_jublia_159416-eng.php
   Google Scholar
• US FDA. Approval Letter: efinaconazole US. 2014. Available from: www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203567Orig1s000ApLtr.pdf
   Google Scholar
• Fouilloux B. [Onychomycosis and quality of life]. Ann Dermatol Vénéréologie. 2003;130:1275–1278.
   PubMed Web of Science ®Google Scholar
• Chang C-H, Young-Xu Y, Kurth T, et al. The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. Am J Med. 2007;120:791–798.
   PubMed Web of Science ®Google Scholar
• Del Rosso JQ. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents. J Clin Aesthetic Dermatol. 2014;7:10–18.
   PubMedGoogle Scholar
• Gupta AK, Daigle D, Foley KA. Network meta-analysis of onychomycosis treatments. Skin Appendage Disord. 2015;1:74–81.
   PubMed Web of Science ®Google Scholar